February 7, 2008 - Abiomed Inc. reported its third quarter fiscal 2008 revenue reached $16.0 million, up 24 percent compared to revenue of $12.9 million for the same period of fiscal 2007, marking a revenue high for Abiomed.
Total revenue for the third quarter of fiscal 2008 was, and Revenue in both the U.S. and Europe were also record highs for a quarter. Revenue for the nine months ended December 31, 2007 was $41.4 million, up 13 percent compared to revenue of $36.8 million in the first nine months of fiscal 2007.
During the third quarter of fiscal 2008 compared to the third quarter of fiscal 2007, Impella disposable revenue increased 192 percent, AB5000(R) disposable revenue increased 4 percent and BVS 5000 disposable revenue declined 3 percent. During the third quarter of fiscal 2008 compared to the third quarter of fiscal 2007, Impella console revenue increased 100 percent and AB5000 console revenue decreased 12 percent.
Abiomed today updated its full year revenue forecast for its fiscal year 2008 ending March 31, 2008, to be in the range of $58 million to $62 million based on the timing of U.S. clinical trials and global regulatory approvals of new products. This forecast would be an increase over fiscal 2007 of approximately 15 to 22 percent.
For more information: www.abiomed.com